Five-year outcomes with first-line (1L) nivolumab + ipilimumab + chemotherapy (N + I + C) vs C in patients (pts) with metastatic NSCLC (mNSCLC) in CheckMate 9LA.

Authors

Martin Reck

Airway Research Center North, German Center for Lung Research, LungenClinic, Grosshansdorf, Germany

Martin Reck , Tudor-Eliade Ciuleanu , Michael Schenker , Stephanie Bordenave , Manuel Cobo , Oscar Juan-Vidal , Niels Reinmuth , Eduardo Richardet , Enriqueta Felip , Juliana Menezes , Ying Cheng , Hideaki Mizutani , David Paul Carbone , Shun Lu , Tom John , Takekazu Aoyama , Javed Mahmood , Nan Hu , Laura Eccles , Luis G. Paz-Ares

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT03215706

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 8560)

DOI

10.1200/JCO.2024.42.16_suppl.8560

Abstract #

8560

Poster Bd #

424

Abstract Disclosures

FEATURED

Five-year outcomes with first-line (1L) nivolumab + ipilimumab + chemotherapy (N + I + C) vs C in patients (pts) with metastatic NSCLC (mNSCLC) in CheckMate 9LA.

Authors

Martin Reck

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Poster Details

Meeting

Session Type

Session Title

Track

Sub Track

Clinical Trial Registration Number

Citation

DOI

Abstract #

Poster Bd #

Similar Posters

Poster

First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients (pts) with metastatic non–small cell lung cancer (NSCLC): 3-year update from CheckMate 9LA.

Poster

SUNRAY-01, a pivotal, global study of olomorasib (LY3537982) in combination with pembrolizumab with or without chemotherapy for 1L treatment in KRAS G12C-mutant advanced NSCLC.

Poster

First-line (1L) nivolumab (N) + ipilimumab (I) + chemotherapy (C) vs C alone in patients (pts) with metastatic NSCLC (mNSCLC) from CheckMate 9LA: 4‑y clinical update and outcomes by tumor histologic subtype (THS).

Poster

A phase 2/3 study of fianlimab plus cemiplimab versus cemiplimab in patients with advanced non-small cell lung cancer with tumors expressing PD-L1 ≥50%.